Theracurmin® Research & Clinical Trials
Anti-inflammatory Benefits of Curcumin
The importance of curcumin as an anti-inflammatory agent and its potential for beneficial, healing effects is the driving force behind curcumin research. Additionally curcumin has been shown to exhibit antioxidant, antiviral, antibacterial, antifungal, and anti-cancer properties. At Theravalues, we believe our Theracurmin® Highly Bioavailable Curcumin product has the potential to act as a protectant against many of today’s diseases.
Diseases Caused by Chronic Inflammation
The human body can harbor chronic inflammation that is detrimental to health. Inflammation is the basis of many physiological and pathological processes. Much is known about how inflammation is initiated, develops and evolves over the short term. But less is known about the causes and consequences of chronic, long-term inflammation that underlies many human diseases. Recent studies have expanded our understanding of the dialogue between inflammatory responses and physiological and pathological responses.
Potential Benefits of Theracurmin®
Highlights from some of the key studies follow and clearly show Theracurmin® has the potential to provide substantial benefits in many areas of human health.
Detoxification / Alcohol Metabolism
Acetaldehyde is an alcohol metabolite and known as a cause of hangover. Recently it has been reported that acetaldehyde is strongly related to various diseases. In the human clinical trial, seven healthy volunteers participated by drinking the same amount of alcohol (.05mL ethanol/kg weight). After 30 minutes, those who consumed a follow-up Theracurmin® beverage containing 30 mg of curcumin lowered their blood-acetaldehyde concentration significantly (25%) when compared to those who drank water alone (control). The study confirmed that Theracurmin® has a positive effect on the alcohol metabolism in healthy volunteers.
(Sasaki H., et al: Biol Pharm Bull.34(5):660-665, 2011)
Detoxification / Liver Function
In another study, Theracurmin® was orally administrated to healthy volunteers, including those with relatively high values for liver function markers such as gamma-glutamyl transpeptidase (γ-GTP), aspartate transaminase (AST), and alanine transaminase (ALT), at a dose of 180 mg of curcumin daily for 1 month. Significant decreases were observed in AST (−12%), ALT (−16%), and γ-GTP (−15%). Further, liver function was more markedly improved in subjects who had higher baseline values than in those with relatively normal ones.
(Otsuka Y, et al: The Journal of Japan Mibyou System Association 16(2):331-333, 2010)
Skin Care, Anti-aging
While acting as both an anti-oxidant and anti-inflammatory agent to protect skin from stress caused by UV rays, research has found that ingesting Theracurmin® can improve skin condition with increased moisture levels (at a dose of 60 mg of curcumin daily) and reduction of age spots (at a dose of 180 mg curcumin daily).
Recovery from Muscle Fatigue
In crossover human clinical trials, Theracurmin® consumption at a dose of 150 mg of curcumin before and after exercise contributed to significantly faster recovery of muscle strength after extreme exercise. Additionally, creatine kinase (CK) activity in the blood — which is commonly used as a marker of muscle fiber damage — was attenuated in the Theracurmin® group.
(Tanabe Y, et al: Eur J Appl Physiol 115:1949–1957, 2015)
A double-blind clinical trial of 68 patients has shown that Theracurmin® can have positive effects on diastolic function in hypertensive patients with left ventricular hypertrophy. The patient group that ingested 60mg of curcumin a day for 24 weeks had a 12.7% reduction in LV stiffness (E/E’) when compared to the patient group that ingested a placebo. Left ventrical diastolic failure was less severe in the heart hypertrophy patients that consumed the Theracurmin doses. This may lead toward treatment and prevention of disastolic heart failure.
(American Heart Association, Nov.12-16, 2011 / American College of Cardiology, March 26, 2012)
Multiple studies of double-blind clinical trials have been conducted to assess the effects of Theracurmin® on the arterial health of postmenopausal women. A combination of Theracurmin® ingestion (150mg of curcumin a day) and exercise training for 8 weeks was shown to significantly improve arterial compliance, vascular endothelial function and central arterial hemodynamics.
(Akazawa N., et al: Artery Research 7(1):67-72, 2013)
(Akazawa N., et al: Nutr Res 32(10):795-799, 2012)
(Sunagawa J., et al: Am J Hypertens, Vol 25-6, 651-656, 2012)
In this study, Theracurmin® was administered at a daily oral dose of 200mg or 400mg of curcumin along with Gemcitabine-based chemotherapy to 16 patients with refractory pancreatic or biliary tract cancer. The study documented their significantly improved quality of life scores by quantifying their experiences with fatigue, functional abilities, diarrhea, financial difficulties and appetite loss. 21% of the patients that ingested Theracurmin® during their treatment could survive more than one year.
(Kanai M., et al: Cancer Chemother Pharmacol. 30 March, 2013 Published online)
In a double-blinded, placebo-controlled, randomized, 8-week trial, 50 patients with medial knee osteoarthritis, aged 40 years or older, were divided into two groups of 25 people. The Theracurmin® group was given 180mg of curcumin a day and the results clearly indicated they experienced a significant reduction of knee pain when compared to the placebo group. In addition, the Theracurmin® group was able to reduce their dependence on NSAIDs to alleviate their pain.
(Nakagawa Y., et al: J Orthrop Sci. Vol. 19, Nov. 6, 2014)
Exercise-induced Oxidative Stress
In a doubled-blinded, placebo-controlled, counterbalanced crossover trial, Theracurmin® supplementation at a dose of 90mg of cur cumin two hours before exercise or two hours before and immediately after exercise significantly increased the serum concentration of biological antioxidant potential (BAP) and reduced glutathione (GSH).
(Takahashi et al. Int J Sports Med. 34: 1-7, 2013)
COPD (Chronic Obstructive Pulmonary Disease)
Research to be published soon.
Research to be published soon.
Ongoing Clinical Trials
|Progressing malignancies||MD Anderson Cancer Center, University of Texas|
|NASH||Kyoto University Hospital|
|Mild cognitive impairment||UCLA|
|Heart failure / diastolic dysfunction: dose
|Kyoto Medical Center|
|Cachectic condition||Keio University|
|Schizophrenia||UCLA(VA Greater Los Angeles Healthcare System)
|Osteoarthritis||Kyoto Medical Center|
|Crohn’s disease||Hamamatsu Minami Hospital|
|Prostate-Specific Antigen after surgery||Teikyo University|